Cynata Therapeutics Ord Shs V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ord Shs > BYD is the first OEM domino to fall in mine buying

<< Previous

Bullboard Posts

Next >>

Comment by tiger2201on Jun 06, 2022 7:22pm

314 Views

Post# 34735599

RE:RE:RE:RE:RE:RE:RE:BYD is the first OEM domino to fall in mine buying

When I read the NR, then I will believe it! LOL. How long has the pilot plant running? Woun't they say, end of December, then end of Q1, now end of Q2. When this management set up a time line, you need X3.

tiger

on-target wrote: Off-site treatment of a solution to produce a final lithium product from the pilot plant is expected by the end of this month.

See this under "Catalysts Upcoming" in this article

https://goldnewsletter.com/go060222/

Also, this May 13 2022, video

https://www.youtube.com/watch?v=IGBzcDXwh7o